Deltex Medical Group plc provided revenue guidance for the second half of 2022. The Board's expectation for the second half of 2022 is that the number of elective procedures in the UK and USA will increase and access into hospitals will improve for teams of clinical educators and sales experts. This, along with the anticipated European launch of next generation TrueVue monitor, which includes a novel non-invasive modality, later this year is expected to drive higher revenues.